Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.
The Company is publicly traded on the Toronto Stock Exchange (TSX: BNC).
The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.
For recent media coverage of Bioniche Life Sciences Inc. click here >>
August 22, 2014
Bioniche Life Sciences Announces Terms of $5 Million Financing & Use of Proceeds
August 21, 2014
Bioniche Life Sciences Announces Overnight Marketed Offering
August 19, 2014
Bioniche Announces Q1/2015 Timeline for the Filing of a Biologics License Application for Marketing Approval of MCNA in the United States